Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Kelly, W., Srinivas, S., Maly, J., Kilari, D., Hussain, A., Saraiya, B., Siddiqui, B., Monk, P., Chatta, G. S., Narayan, V., Rana, D., Thanigaimani, P., Fang, F., Skokos, D., Kirshner, J., Seebach, F. A., Lowy, I., Ingham, M., Sandigursky, S., Miller, E. LIPPINCOTT WILLIAMS & WILKINS. 2025: TPS295View details for DOI 10.1200/JCO.2025.43.5_suppl.TPS295
View details for Web of Science ID 001454810200048